Cargando…
Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia
Encenicline is a novel, selective α7 nicotinic acetylcholine receptor agonist in development for treating cognitive impairment in schizophrenia and Alzheimer's disease. A phase 2, double-blind, randomized, placebo-controlled, parallel-design, multinational study was conducted. Patients with sch...
Autores principales: | Keefe, Richard SE, Meltzer, Herbert A, Dgetluck, Nancy, Gawryl, Maria, Koenig, Gerhard, Moebius, Hans J, Lombardo, Ilise, Hilt, Dana C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864641/ https://www.ncbi.nlm.nih.gov/pubmed/26089183 http://dx.doi.org/10.1038/npp.2015.176 |
Ejemplares similares
-
TC299423, a Novel Agonist for Nicotinic Acetylcholine Receptors
por: Wall, Teagan R., et al.
Publicado: (2017) -
The effective opening of nicotinic acetylcholine receptors with single agonist binding sites
por: Williams, Dustin K., et al.
Publicado: (2011) -
Structural model of nicotinic acetylcholine receptor isotypes bound to acetylcholine and nicotine
por: Schapira, Matthieu, et al.
Publicado: (2002) -
Nicotinic acetylcholine receptor agonist attenuates ILC2-dependent airway hyperreactivity
por: Galle-Treger, Lauriane, et al.
Publicado: (2016) -
Investigation of the Possible Pharmacologically Active Forms of the Nicotinic Acetylcholine Receptor Agonist Anabaseine
por: Andrud, Kristin, et al.
Publicado: (2019)